A recent lawsuit filed in California by Amylin Pharmaceuticals against Eli Lilly claims that the drugmaker violated a marketing agreement of their joint diabetes drug Byetta. According to the complaint, Eli Lilly broke federal laws and engaged in anti-competitive practices by marketing and manufacturing Tradjenta, a diabetes drug that would reportedly act as a competitor against Byetta. Both Amylin and Eli Lilly are currently facing a large number of Byetta lawsuits that have been filed on behalf of individuals who have been diagnosed with pancreatitis after taking the drug.
Free Byetta Case Evaluation: If you or a loved one has been injured by Byetta, you should contact our law firm immediately. You may be entitled to compensation by filing a lawsuit and we can help.
What’s the problem?
May 17, 2011 – A new Byetta lawsuit has been filed by Amylin Pharmaceuticals against Eli Lilly, claiming that the company violated a marketing agreement by partnering with Boehringer Ingelheim to develop and market Tradjenta, a similar diabetes drug recently approved by the FDA.
According to the complaint, Amylin claims that Tradjenta would be in direct competition with Byetta, and Eli Lilly would be able to use the same marketing people on both drugs, giving the company the ability to choose which diabetes medication is promoted better. Eli Lilly responded promptly by denying that Tradjenta would compete with Byetta, and claimed that no crime had been committed in partnering with Boehringer Ingelheim.
Side Effects of Byetta
Since 2007, Byetta has been linked to numerous reports of serious and potentially life-threatening injuries in some users. Studies have found an association between Byetta side effects and pancreatitis, kidney problems and other injuries. Byetta lawsuits are currently being investigated for individuals diagnosed with the following conditions:
- Pancreatic Cancer
- Acute Pancreatitis
- Hemorrhagic Pancreatitis
- Necrotizing Pancreatitis
- Impaired Kidney Function
- Renal failure
- Kidney Failure
In August 2008, the U.S. Food and Drug Administration (FDA) issued a warning about the potential link between acute pancreatitis and patients taking Byetta. The agency reported on its website that of the 6 cases reported, all patients were hospitalized, and two of the patients died. Signs and symptoms of Byetta-induced pancreatitis include:
- severe pain centered in the upper middle or upper right part of the abdomen
- swollen abdomen
- rapid heartbeat
- low blood pressure
- confusion or difficulty concentrating
According to a March 2009 Drug Safety Update article about Byetta:
Up to February 2009, we have received six case reports of pancreatitis and a further three cases of acute pancreatitis in the UK…. 396 case reports of pancreatitis have been received worldwide in association with [Byetta (exenatide)] up to September 2008 (mostly from the USA). 80% of these reports were considered to be possibly related to exenatide, and in several cases there was evidence of positive rechallenge. Nine reports of necrotising or haemorrhagic pancreatitis have been received worldwide, two of which had a fatal outcome. After a Europe-wide review, product information for exenatide is being updated to contain further information about this risk.
Do I have a Byetta Lawsuit?
The Product Liability & Defective Drug Litigation Group at our law firm is an experienced team of trial lawyers that focus on the representation of plaintiffs in Byetta lawsuits. We are handling individual litigation nationwide and currently accepting new pancreatitis cases in all 50 states.